Biotech Values

[DewDiligence]

Tysabri still growing but growth rate is declining. Here are the numbers reported today by BIIB:

3Q08 worldwide Tysabri sales were $236M, +18% QoQ, +154% YoY.

The number of worldwide commercial patients on Tysabri at 30-Sep-2008 was 34,800, +12% QoQ, +118% YoY.

If the growth rate seen from 2Q08 to 3Q08 is maintained, it will take ten quarters — i.e. until the first quarter of 2011 — for Tysabri sales to reach the 100,000-patient goal set forth by BIIB and ELN.

Some analysts do not think the 100,000-patient target will ever be met: #msg-31249570.




<font size=3><font color=red> “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”